Epstein Secrets

From: "Jeffrey E." <[email protected]> To: Richard Kahn Subjec

From: "Jeffrey E." <[email protected]> To: Richard Kahn Su

ive opportunity and are reiterating our Buy rating. For MYL, little credit is given to the stock for Copaxone (especially with recent concerns over EpiPen pricing) & note that MYL has still yet to receive approval for Ix Copaxone & is awaiting approval for 3TW. Sumant models $100mm/yr in sales for Cop

<[email protected]> To: Richard Kahn Subject: Re: Add to TEVA and AGN Date: Thu, 25 Aug 2016 16:36:10 +0000 Dumb On Thursday, 25 August 2016, jeffrey E. <[email protected]> wrote: no On Thu, Aug 25, 2016 at 11:34 AM, Richard Kahn < > wrote: amanda is recommending we add to the two convertible pr

From: "Jeffrey E." <[email protected]> To: Richard Kahn Sub

ive opportunity and are reiterating our Buy rating. For MYL, little credit is given to the stock for Copaxone (especially with recent concerns over EpiPen pricing) & note that MYL has still yet to receive approval for lx Copaxone & is awaiting approval for 3TW. Sumant models $100mrn/yr in sales for Co

From: Richard Kahn • To: "Jeffrey E." <[email protected]> Subject: Re: Add to

h Floor New York, NY 10022 tel faxcell On Aug 25, 2016, at 12:36 PM, jeffrey E. [email protected]> wrote: Dumb On Thursday, 25 August 2016, jeffrey E. <[email protected]> wrote: no On Thu, Aug 25, 2016 at 11:34 AM, Richard Kahn • > wrote: amanda is recommending we add to the two convertible pre

ive opportunity and are reiterating our Buy rating. For MYL, little credit is given to the stock for Copaxone (especially with recent concerns over EpiPen pricing) & note that MYL has still yet to receive approval for lx Copaxone & is awaiting approval for 3TW. Sumant models $100mm/yr in sales for Cop

From: Kathy Ruemmler Sent: Tuesday, November 22, 2016 1:32 PM To: Jeffrey E. Subject: Fwd: Begin forwarded=message: From: =ate: November 22, 2016 at 8:30:34 AM EST To: =/blockquote> The National Law Journal Mylan Won't

Sent: Tuesday, November 22, 2016 1:32 PM To: Jeffrey E. Subject: Fwd: Begin forwarded=message: Fro

now a company is following its bad=example. Taxpayers have paid and based on reports, continue to pay, hundred= of millions of dollars more for the EpiPen than they have to pay. This hap=ened because either the agencies in charge dropped the ball, the company ga=ed the system, or both. Ironically, the